Skip to content
Medical Health Aged Care

KFSH&RC Celebrates 25 Scientists Named in Stanford’s Top 2% Most-Cited Researchers Worldwide

King Faisal Specialist Hospital & Research Centre 2 mins read

E'24-026_BDA_26715

RIYADH, Saudia Arabia, Jan. 16, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre honored 25 scientists who joined Stanford University's prestigious list, marking them among the 'top 2% most-cited scientists' list updated in October 2023.

The recent release recognizes 25 distinguished KFSH&RC scientists, among the top 2% most-cited researchers worldwide in 2021-2022, and acknowledges their overall career accomplishments. This prestigious recognition celebrates the outstanding contributions and impact of KFSH&RC researchers on the global scientific stage, highlighting KFSH&RC's steady commitment to advancing healthcare through novel research. It elevates its international reputation as a pioneer hub for innovative research.

His Excellency Dr. Majid Al Fayyadh, Chief Executive Officer, KFSH&RC, stated: "We are incredibly proud of this recognition, a testament to our firm commitment to advancing healthcare through cutting-edge research and innovation at home and beyond. This new milestone reflects the dedication and expertise of our exceptional team of scientists and medical professionals who continually push the boundaries of knowledge. At KFSH&RC, we remain dedicated to our mission to shape the future of healthcare and contribute to global advancements in the field."

Renowned for its annual compilation, Stanford University highlights the remarkable achievements of scientists whose research has reaped the highest citations in international and scientific journals. The university unveils a list featuring 180,000 researchers representing the top 2% of most-cited scientists globally each year. This compilation covers 22 research fields and 176 subfields, utilizing citation metrics from the Scopus database.

KFSH&RC extends heartfelt congratulations to researchers recognized for the year 2021-2022. Each scientist left an indelible mark in various medical fields. Their contributions exemplify KFSH&RC's commitment to excellence and leadership in healthcare innovation.

This recognition further enhances KFSH&RC's reputation as a holistic healthcare hub, highlighting its dedication to building a resilient healthcare system through continuous research and advancement, in line with Vision 2030.

For more information, please visit www.kfshrc.edu.sa or contact our media team at mediacoverage@kfshrc.edu.sa.

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/44867e95-bfa4-49d6-b4c5-123d624d9de3


Primary Logo

More from this category

  • Medical Health Aged Care
  • 16/01/2025
  • 08:41
Mainstay Medical Holdings plc

Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8®

ReActiv8® Restorative NeurostimulationTM demonstrated statistically significant and clinically meaningful superiority vs. standard of care in all primary and secondary measures of disability, pain and…

  • Contains:
  • Medical Health Aged Care
  • 16/01/2025
  • 06:05
Royal Australian College of GPs

ADHD reform more urgent in NSW with psychiatrists’ workforce crisis

The Royal Australian College of GPs is urging the New South Wales Government to prioritise reforms to improve access to support and treatment for people with attention deficit hyperactivity disorder (ADHD) from GPs after the mass resignation of psychiatrists. Around 200 psychiatrists in NSW's public health system have submitted their resignations amid an ongoing pay dispute with the state government. RACGP New South Wales Chair Dr Rebekah Hoffman said: “GPs should be able to initiate and prescribe medications for people living with ADHD, and manage their care. Allowing GPs to give more support to people living with ADHD will improve…

  • Medical Health Aged Care
  • 16/01/2025
  • 05:00
GlaxoSmithKline

Local scientific discovery Omjarra (momelotinib) now TGA approved for Australians with rare bone marrow cancer

Embargoed: 06.00am Thursday 16th January 2025, MELBOURNE, AUSTRALIA Omjjara (momelotinib) was discovered by Melbourne scientists in 2005.1 Today’s TGA approval follows its recent FDA approval and makes it one of only a handful of original Australian scientific discoveries to secure both milestones.1-6 Omjjara is a once daily pill indicated to treat disease-related consequences of primary or secondary myelofibrosis including spleen enlargement and moderate to severe anaemia.7 Myelofibrosis is a rare bone marrow cancer with an average survival of 5-7 years.7-8 GSK Australia welcomes the Therapeutic Goods Administration (TGA) approval of Omjjara - a local scientific discovery now providing the first…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.